The potential prize of pharmacy-level substitution as well as a year of first interchangeable biosimilar exclusivity for Alvotech’s proposed AVT02 higher-strength 100mg/ml adalimumab biosimilar has moved a step closer.
The US Food and Drug Administration has accepted for review the company’s biologics licensing application for AVT02 that includes new data supporting